Drug Profile
Research programme: immune disorder therapeutics - Lycera
Alternative Names: Bz-423; LYC-53976Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Lycera
- Class Antifibrotics; Immunotherapies; Small molecules
- Mechanism of Action Adenosine triphosphatase modulators; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Fibrosis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
- 16 Jul 2020 Preclinical development of ATPase modulators is ongoing for Autoimmune disorders in USA (Lycera pipeline, July 2020)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb